FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

20 letters match. Newest first.

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  5. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  6. Verdure Sciences, Inc.

    FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.

    High risk
  7. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  8. Shirish M. Gadgeel, M.D.

    Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.

    High risk
  9. American Behavioral Research Institute, LLC

    FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.

    High risk
  10. United Health Products, Inc.

    FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.

    High risk
  11. Americo F. Padilla, M.D.

    FDA warns clinical investigator Americo F. Padilla, M.D. over failing to obtain parental consent before enrolling pediatric subjects in drug trials.

    High risk
  12. ISOThrive, Inc.

    ISOThrive ran two human studies of a supplement used as a drug without submitting a required IND.

    High risk
  13. Massachusetts Institute of Technology MIT

    FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.

    Medium
  14. Ward Smelling Salts

    FDA warns Canadian maker Ward Smelling Salts that its ammonia inhalant products are unapproved new drugs sold illegally in the U.S.

    High risk
  15. Antonio E. Blanco, M.D./Vista Health Research, LLC

    FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.

    High risk
  16. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  17. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  18. Equine Podiatry Solutions, LLC

    Equine Podiatry Solutions marketed Desmosphyrine, an unapproved new animal drug, for treating laminitis in horses.

    High risk
  19. RAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.

    FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.

    High risk
  20. Kaleido Biosciences, Inc.

    Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.

    High risk